Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S1470-2045(11)70065-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
BreVamiR3': A comprehensive database for breast cancer-associated genetic variations in miRNA and 3' UTR of their target genes.
Comput Biol Med
December 2024
Department of Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda, Punjab, India. Electronic address:
Breast cancer (BC) is a multifactorial disease where microRNA (miRNA)-mediated dysregulated gene expression plays a pivotal role in tumorigenesis, progression, and clinical outcomes. Genetic variation, particularly SNPs in miRNA sequences and the 3' untranslated regions (3'UTRs) of their target genes, can disrupt miRNA-mRNA interactions, leading to altered gene expression. Despite several existing databases providing insights into various aspects of miRNAs and their target genes in association with the development of the disease.
View Article and Find Full Text PDFAssociation of 3'UTR variations of EGFR and KRAS oncogenes with clinical parameters in lung cancer tumours.
Biol Cell
August 2024
Department of Medical Genetics, School of Medicine, Selcuk, University, Selcuklu, Konya, Turkey.
Bacground Information: Lung cancer is one of the leading types of cancer deaths worldwide, with approximately 2 million people diagnosed with lung cancer each year. In this study, we aimed to determine the exonic and 3'UTR sequences of EGFR, PIK3CA and KRAS genes in 39 sporadic lung cancer tumors and to reveal the changes in the miRNA binding profile of tumors with somatic variation in the 3'UTR region and to examine the relationship of these changes with clinical parameters.
Results: A statistically significant correlation was found between the presence of miRNA that could not bind to the 3'UTR region due to variation in at least one of the EGFR or KRAS genes and the presence of metastasis in the tumor.
The RAS oncogene in brain tumors and the involvement of let-7 microRNA.
Mol Biol Rep
April 2024
Department of Science, Roma Tre University, Viale Guglielmo Marconi 446, 00146, Rome, Italy.
RAS oncogenes are master regulator genes in many cancers. In general, RAS-driven cancers have an oncogenic RAS mutation that promotes disease progression (colon, lung, pancreas). In contrast, brain tumors are not necessarily RAS-driven cancers because RAS mutations are rarely observed.
View Article and Find Full Text PDFAlbumin promoter-driven FlpO expression induces efficient genetic recombination in mouse liver.
Am J Physiol Gastrointest Liver Physiol
May 2024
Department of Cancer Biology, Mayo Clinic, Jacksonville, Florida, United States.
Tissue-specific gene manipulations are widely used in genetically engineered mouse models. A single recombinase system, such as the one using Alb-Cre, has been commonly used for liver-specific genetic manipulations. However, most diseases are complex, involving multiple genetic changes and various cell types.
View Article and Find Full Text PDFDeciphering the role of KRAS gene in oncogenesis: Focus on signaling pathways, genetic alterations in 3'UTR, KRAS specific miRNAs and therapeutic interventions.
Crit Rev Oncol Hematol
February 2024
Department of Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda, Punjab, India. Electronic address:
Cancer is a significant cause of death after cardiovascular disease. The genomic, epigenetic and environmental factors have been found to be the risk factor for the disease. The most important genes that develop cancer are oncogenes and tumor suppressor genes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!